FEATURED

TG4010 Vaccine Plus Chemo Appears Effective

TG4010 immunotherapy plus first-line chemotherapy appeared to improve progression-free survival in advanced non-small cell lung cancer.

KRAS, BRAF V600, Lower Survival

Post-hoc analysis of the PETACC-8 trial tied KRAS and BRAF V600E mutations to shorter overall and disease-free survival in microsatellite stable (MSS) colon cancer.

Drug Showcase: PORTRAZZA (necitumumab)

Indicated for metastatic squamous non-small cell lung cancer.

Immunotherapy: Top Advance of the Year

Immunotherapy is the American Society of Clinical Oncology's top cancer advance of the year.

Tool Connects Pts. With Fertility Clinics

While researchers seek better methods to preserve ovarian function, new tools are being developed to help clinicians better inform patients about their options.

Metformin and Pancreatic Cancer

Metformin, traditionally used as a first-line treatment for type 2 diabetes, may be able to reduce a potential source of energy for certain cancer cells.

Neutrophil-to-lymphocyte Ratio Not Ready

Neutrophil-to-lymphocyte ratio is an attractive candidate prognostic biomarker for patients with cancer, but mixed study results draw cautions.

ONA Navigation Summit 2016

Recommended stopping points for surveillance for renal cell carcinoma are oversimplified and should be replaced with a more risk-stratified approach.

Looking for a Job?

Access our job board to view over 1,​200 job openings throughout the US.

Treatment Regimens

A full listing of cancer treatment and drug information is available to access.

Viewpoints

TG4010 Vaccine Plus Chemo Appears Effective in Advanced NSCLC

TG4010 Vaccine Plus Chemo Appears Effective in Advanced NSCLC

TG4010 immunotherapy plus first-line chemotherapy appeared to improve progression-free survival in advanced non-small cell lung cancer.

KRAS, BRAF V600 Tied to Lower Survival in Microsatellite Stable Colon Cancer Tumors

KRAS, BRAF V600 Tied to Lower Survival in Microsatellite Stable Colon Cancer Tumors

Post-hoc analysis of the PETACC-8 trial tied KRAS and BRAF V600E mutations to shorter overall and disease-free survival in microsatellite stable (MSS) colon cancer.

Feature Articles

Elevated Imatinib Dose, Second-generation TKIs Have Superior Responses in CML

Elevated Imatinib Dose, Second-generation TKIs Have Superior Responses in CML

Complete cytogenetic response was found to be higher in patients treated with elevated doses of imatinib and second-generation TKIs.

Managing Symptoms Is Key for Patients With Metastatic Cancer Who Continue to Work

Managing Symptoms Is Key for Patients With Metastatic Cancer Who Continue to Work

Patients with metastatic cancer who continue to work may need the income or access to health insurance or simply have the desire to work, yet they face a number of hurdles.

A New Era in Treating Multiple Myeloma

A New Era in Treating Multiple Myeloma

The treatment of multiple myeloma has dramatically changed over the past year.

2015 FDA Drug Approvals for Metastatic Lung Cancer Highlight Advances in Personalized Medicine

2015 FDA Drug Approvals for Metastatic Lung Cancer Highlight Advances in Personalized Medicine

A comprehensive review of the 6 drugs approved for the treatment of patients with metastatic squamous and nonsquamous non-small cell lung cancer.

Sign Up for Free e-newsletters

Regimen and Drug Listings

GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION

Bone Cancer Regimens Drugs
Brain Cancer Regimens Drugs
Breast Cancer Regimens Drugs
Endocrine Cancer Regimens Drugs
Gastrointestinal Cancer Regimens Drugs
Gynecologic Cancer Regimens Drugs
Head and Neck Cancer Regimens Drugs
Hematologic Cancer Regimens Drugs
Lung Cancer Regimens Drugs
Other Cancers Regimens
Prostate Cancer Regimens Drugs
Rare Cancers Regimens
Renal Cell Carcinoma Regimens Drugs
Skin Cancer Regimens Drugs
Urologic Cancers Regimens Drugs